TY - JOUR
T1 - Free 25-hydroxyvitamin D
T2 - Impact of vitamin D binding protein assays on racial-genotypic associations
AU - Osteoporotic Fractures in Men (MrOS) Research Group
AU - Nielson, Carrie M.
AU - Jones, Kerry S.
AU - Chun, Rene F.
AU - Jacobs, Jon M.
AU - Wang, Ying
AU - Hewison, Martin
AU - Adams, John S.
AU - Swanson, Christine M.
AU - Lee, Christine G.
AU - Vanderschueren, Dirk
AU - Pauwels, Steven
AU - Prentice, Ann
AU - Smith, Richard D.
AU - Shi, Tujin
AU - Gao, Yuqian
AU - Schepmoes, Athena A.
AU - Zmuda, Joseph M.
AU - Lapidus, Jodi
AU - Cauley, Jane A.
AU - Bouillon, Roger
AU - Schoenmakers, Inez
AU - Orwoll, Eric S.
N1 - Funding Information:
The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health (NIH) funding. The following institutes provide support: the National Institute on Aging, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences, and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. The research in the United Kingdom and The Gambia were funded by the Medical Research Council (program codes U105960371, U123261351, MC-A760-5QX00) and the Department for International Development (DFID) under the MRC/DFID Concordat agreement. Additionally, portions of the experimental work described herein were performed in the Environmental Molecular Sciences Laboratory, a national scientific user facility sponsored by the Department of Energy and located at Pacific Northwest National Laboratory, which is operated by Battelle Memorial Institute for the Department of Energy under Contract DE-AC05-76RL0 1830. Portions of this work were supported by NIHP41GM103493 (to R.D.S.). Free 25OHD assay provided by DIAsource ImmunoAssays SA (Belgium) and Future Diagnostics Solutions BV (Netherlands), an ELISA based on DIAsource patented monoclonal antibodies. C.M.N. is funded by NIAMS K01 AR062655. K.S.J., I.S., and A.P. were funded by the Medical Research Council (program codes U105960371, U123261351, MC-A760-5QX00) and the DFID under the MRC/DFID Concordat agreement. M.W. and J.S.A. were funded under NIAMS R01 AR063910. C.M.S. is supported by NIH grant T32 DK007674-20. D.V. receives funding from the Research Foundation Flanders (grant number G. 0858.11) and a grant from the KU Leuven (GOA 15/0/01). C.G.L. receives support from a VA Clinical Science Research and Development Career Development Award, Project number 5IK2CW000729-02. S.P. is supported by the Fund for Scientific Research Flanders (Clinical Fellowship grant 1700314N).
Publisher Copyright:
Copyright © 2016 by the Endocrine Society
PY - 2016/5
Y1 - 2016/5
N2 - Context: Total 25-hydroxyvitamin D (25OHD) is a marker of vitamin D status and is lower in African Americans than in whites. Whether this difference holds for free 25OHOD (f25OHD) is unclear, considering reported genetic-racial differences in vitaminDbinding protein (DBP) used to calculate f25OHD. Objectives: Our objective was to assess racial-geographic differences in f25OHD and to understand inconsistencies in racial associations with DBP and calculated f25OHD. Design: This study used a cross-sectional design. Setting: The general community in the United States, United Kingdom, and The Gambia were included in this study. Participants: Men in Osteoporotic Fractures in Men and Medical Research Council studies (N = 1057) were included. Exposures: Total 25OHD concentration, race, and DBP (GC) genotype exposures were included. Outcome Measures: Directly measured f25OHD, DBP assessed by proteomics, monoclonal and polyclonal immunoassays, and calculated f25OHD were the outcome measures. Results: Total 25OHD correlated strongly with directly measured f25OHD (Spearman r = 0.84). Measured by monoclonal assay, mean DBP in African-ancestry subjects was approximately 50% lower than in whites, whereas DBP measured by polyclonal DBP antibodies or proteomic methods was not lower in African-ancestry. Calculated f25OHD (using polyclonal DBP assays) correlated strongly with directly measured f25OHD (r = 0.80-0.83). Free 25OHD, measured or calculated from polyclonal DBP assays, reflected total 25OHD concentration irrespective of race and was lower in African Americans than in US whites. Conclusions: Previously reported racial differences in DBP concentration are likely from monoclonal assay bias, as there was no racial difference in DBP concentration by other methods. This confirms the poor vitamin D status of many African-Americans and the utility of total 25OHD in assessing vitamin D in the general population.
AB - Context: Total 25-hydroxyvitamin D (25OHD) is a marker of vitamin D status and is lower in African Americans than in whites. Whether this difference holds for free 25OHOD (f25OHD) is unclear, considering reported genetic-racial differences in vitaminDbinding protein (DBP) used to calculate f25OHD. Objectives: Our objective was to assess racial-geographic differences in f25OHD and to understand inconsistencies in racial associations with DBP and calculated f25OHD. Design: This study used a cross-sectional design. Setting: The general community in the United States, United Kingdom, and The Gambia were included in this study. Participants: Men in Osteoporotic Fractures in Men and Medical Research Council studies (N = 1057) were included. Exposures: Total 25OHD concentration, race, and DBP (GC) genotype exposures were included. Outcome Measures: Directly measured f25OHD, DBP assessed by proteomics, monoclonal and polyclonal immunoassays, and calculated f25OHD were the outcome measures. Results: Total 25OHD correlated strongly with directly measured f25OHD (Spearman r = 0.84). Measured by monoclonal assay, mean DBP in African-ancestry subjects was approximately 50% lower than in whites, whereas DBP measured by polyclonal DBP antibodies or proteomic methods was not lower in African-ancestry. Calculated f25OHD (using polyclonal DBP assays) correlated strongly with directly measured f25OHD (r = 0.80-0.83). Free 25OHD, measured or calculated from polyclonal DBP assays, reflected total 25OHD concentration irrespective of race and was lower in African Americans than in US whites. Conclusions: Previously reported racial differences in DBP concentration are likely from monoclonal assay bias, as there was no racial difference in DBP concentration by other methods. This confirms the poor vitamin D status of many African-Americans and the utility of total 25OHD in assessing vitamin D in the general population.
UR - http://www.scopus.com/inward/record.url?scp=84969822892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969822892&partnerID=8YFLogxK
U2 - 10.1210/jc.2016-1104
DO - 10.1210/jc.2016-1104
M3 - Article
C2 - 27007693
AN - SCOPUS:84969822892
SN - 0021-972X
VL - 101
SP - 2226
EP - 2234
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 5
ER -